- Home
- DATS vs VCNX Comparison
DATS vs VCNX Comparison
Compare DATS & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- VCNX
- Stock Information
- Founded
- DATS 2014
- VCNX 2001
- Country
- DATS United States
- VCNX United States
- Employees
- DATS N/A
- VCNX N/A
- Industry
- DATS Computer Software: Prepackaged Software
- VCNX Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- VCNX Health Care
- Exchange
- DATS Nasdaq
- VCNX Nasdaq
- Market Cap
- DATS 4.8M
- VCNX 4.5M
- IPO Year
- DATS 2021
- VCNX N/A
- Fundamental
- Price
- DATS $1.90
- VCNX $3.60
- Analyst Decision
- DATS
- VCNX
- Analyst Count
- DATS 0
- VCNX 0
- Target Price
- DATS N/A
- VCNX N/A
- AVG Volume (30 Days)
- DATS 3.5M
- VCNX 125.4K
- Earning Date
- DATS 11-14-2024
- VCNX 11-14-2024
- Dividend Yield
- DATS N/A
- VCNX N/A
- EPS Growth
- DATS N/A
- VCNX N/A
- EPS
- DATS N/A
- VCNX N/A
- Revenue
- DATS $515.00
- VCNX $388,000.00
- Revenue This Year
- DATS N/A
- VCNX N/A
- Revenue Next Year
- DATS N/A
- VCNX N/A
- P/E Ratio
- DATS N/A
- VCNX N/A
- Revenue Growth
- DATS N/A
- VCNX N/A
- 52 Week Low
- DATS $1.01
- VCNX $1.39
- 52 Week High
- DATS $4.13
- VCNX $13.02
- Technical
- Relative Strength Index (RSI)
- DATS 51.15
- VCNX 55.03
- Support Level
- DATS $1.71
- VCNX $3.04
- Resistance Level
- DATS $2.54
- VCNX $3.43
- Average True Range (ATR)
- DATS 0.40
- VCNX 0.40
- MACD
- DATS -0.04
- VCNX 0.05
- Stochastic Oscillator
- DATS 16.26
- VCNX 67.60
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts, even after they are sent.
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.